Clinical trial / 2008
Iron reduction by phlebotomy decreased new visceral malignancy risk and mortality in patients with peripheral arterial disease.
A multicenter trial randomly assigned 1,277 peripheral arterial disease patients to iron reduction by phlebotomy (n = 636) or control (n = 641), followed for an average of 4.5 years. Risk of new visceral malignancy was lower in the iron reduction group compared to control (38 vs 60; HR = 0.65, 95% CI = 0.43 to 0.97; P = .036). Among patients who developed new cancers, those in the iron reduction group had lower cancer-specific mortality (HR = 0.39, 95% CI = 0.21 to 0.72; P = .003) and lower all-cause mortality (HR = 0.49, 95% CI = 0.29 to 0.83; P = .009).
- Study type
- Multicenter randomized, controlled, single-blinded clinical trial
- Who was studied
- 1,277 patients with peripheral arterial disease without visceral malignancy in last 5 years
- What was measured
- New visceral malignancy occurrence and cause-specific mortality
THE PAPER
Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.
Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. J Natl Cancer Inst, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.